Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis
Background Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients. Objectives Our aim was to investigate the impact of BBR on various cancers in healthy animals to promote the transformation from bench to bed. Se...
Gespeichert in:
| Veröffentlicht in: | BMC cancer Jg. 19; H. 1; S. 589 - 20 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
17.06.2019
BioMed Central Ltd Springer Nature B.V BMC |
| Schlagworte: | |
| ISSN: | 1471-2407, 1471-2407 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients.
Objectives
Our aim was to investigate the impact of BBR on various cancers in healthy animals to promote the transformation from bench to bed.
Search methods
PubMed, Embase, Springer, and Cochrane databases were searched from January 2000 to October 2018 for relevant articles.
Selection criteria
Only published studies focusing on the relationship between BBR and various cancers in vivo were qualified. Two review authors independently assessed the risk of bias for each study, and any disagreement was resolved by discussion or by involving a third assessor.
Results
A total of 26 studies from 2000 to 2018, focusing on various cancer types, including breast cancer, liver cancer, colorectal cancer, nasopharyngeal carcinoma, lung cancer, gastric cancer, neuroepithelial cancer, endometrial carcinoma, esophageal cancer, tongue cancer, cholangiocarcinoma, and sarcoma were included. Overall, BBR reduced tumor volume (SMD =3.72, 95% CI: 2.89, 4.56, Z = 8.73,
p
< 0.00001) and tumor weight (SMD =2.35, 95% CI: 1.51, 3.19, Z = 5.50,
p
< 0.00001) in a linear The dose–response relationship (Pearson r = − 0.6717,
p
< 0.0001 in tumor volume analysis; Pearson r = − 0.7704,
p
< 0.0005 in tumor weight analysis). BBR inhibited angiogenesis in tumor tissues (SMD = 4.29, 95% CI: 2.14, 6.44, Z = 3.92,
p
< 0.00001), but it had no significant effect on the body weight of experimental animals (SMD = 0.11, 95% CI: − 0.70, 0.92, Z = 0.27,
p
= 0.78). Publication bias was not detected.
Conclusion
BBR exerted anti-tumor effects in a variety of tumors in vivo, especially breast cancer and lung cancer, and the evidence was still insufficient in colorectal cancer and gastric cancer. |
|---|---|
| AbstractList | Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients.BACKGROUNDNumerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients.Our aim was to investigate the impact of BBR on various cancers in healthy animals to promote the transformation from bench to bed.OBJECTIVESOur aim was to investigate the impact of BBR on various cancers in healthy animals to promote the transformation from bench to bed.PubMed, Embase, Springer, and Cochrane databases were searched from January 2000 to October 2018 for relevant articles.SEARCH METHODSPubMed, Embase, Springer, and Cochrane databases were searched from January 2000 to October 2018 for relevant articles.Only published studies focusing on the relationship between BBR and various cancers in vivo were qualified. Two review authors independently assessed the risk of bias for each study, and any disagreement was resolved by discussion or by involving a third assessor.SELECTION CRITERIAOnly published studies focusing on the relationship between BBR and various cancers in vivo were qualified. Two review authors independently assessed the risk of bias for each study, and any disagreement was resolved by discussion or by involving a third assessor.A total of 26 studies from 2000 to 2018, focusing on various cancer types, including breast cancer, liver cancer, colorectal cancer, nasopharyngeal carcinoma, lung cancer, gastric cancer, neuroepithelial cancer, endometrial carcinoma, esophageal cancer, tongue cancer, cholangiocarcinoma, and sarcoma were included. Overall, BBR reduced tumor volume (SMD =3.72, 95% CI: 2.89, 4.56, Z = 8.73, p < 0.00001) and tumor weight (SMD =2.35, 95% CI: 1.51, 3.19, Z = 5.50, p < 0.00001) in a linear The dose-response relationship (Pearson r = - 0.6717, p < 0.0001 in tumor volume analysis; Pearson r = - 0.7704, p < 0.0005 in tumor weight analysis). BBR inhibited angiogenesis in tumor tissues (SMD = 4.29, 95% CI: 2.14, 6.44, Z = 3.92, p < 0.00001), but it had no significant effect on the body weight of experimental animals (SMD = 0.11, 95% CI: - 0.70, 0.92, Z = 0.27, p = 0.78). Publication bias was not detected.RESULTSA total of 26 studies from 2000 to 2018, focusing on various cancer types, including breast cancer, liver cancer, colorectal cancer, nasopharyngeal carcinoma, lung cancer, gastric cancer, neuroepithelial cancer, endometrial carcinoma, esophageal cancer, tongue cancer, cholangiocarcinoma, and sarcoma were included. Overall, BBR reduced tumor volume (SMD =3.72, 95% CI: 2.89, 4.56, Z = 8.73, p < 0.00001) and tumor weight (SMD =2.35, 95% CI: 1.51, 3.19, Z = 5.50, p < 0.00001) in a linear The dose-response relationship (Pearson r = - 0.6717, p < 0.0001 in tumor volume analysis; Pearson r = - 0.7704, p < 0.0005 in tumor weight analysis). BBR inhibited angiogenesis in tumor tissues (SMD = 4.29, 95% CI: 2.14, 6.44, Z = 3.92, p < 0.00001), but it had no significant effect on the body weight of experimental animals (SMD = 0.11, 95% CI: - 0.70, 0.92, Z = 0.27, p = 0.78). Publication bias was not detected.BBR exerted anti-tumor effects in a variety of tumors in vivo, especially breast cancer and lung cancer, and the evidence was still insufficient in colorectal cancer and gastric cancer.CONCLUSIONBBR exerted anti-tumor effects in a variety of tumors in vivo, especially breast cancer and lung cancer, and the evidence was still insufficient in colorectal cancer and gastric cancer. Background Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients. Objectives Our aim was to investigate the impact of BBR on various cancers in healthy animals to promote the transformation from bench to bed. Search methods PubMed, Embase, Springer, and Cochrane databases were searched from January 2000 to October 2018 for relevant articles. Selection criteria Only published studies focusing on the relationship between BBR and various cancers in vivo were qualified. Two review authors independently assessed the risk of bias for each study, and any disagreement was resolved by discussion or by involving a third assessor. Results A total of 26 studies from 2000 to 2018, focusing on various cancer types, including breast cancer, liver cancer, colorectal cancer, nasopharyngeal carcinoma, lung cancer, gastric cancer, neuroepithelial cancer, endometrial carcinoma, esophageal cancer, tongue cancer, cholangiocarcinoma, and sarcoma were included. Overall, BBR reduced tumor volume (SMD =3.72, 95% CI: 2.89, 4.56, Z = 8.73, p < 0.00001) and tumor weight (SMD =2.35, 95% CI: 1.51, 3.19, Z = 5.50, p < 0.00001) in a linear The dose–response relationship (Pearson r = − 0.6717, p < 0.0001 in tumor volume analysis; Pearson r = − 0.7704, p < 0.0005 in tumor weight analysis). BBR inhibited angiogenesis in tumor tissues (SMD = 4.29, 95% CI: 2.14, 6.44, Z = 3.92, p < 0.00001), but it had no significant effect on the body weight of experimental animals (SMD = 0.11, 95% CI: − 0.70, 0.92, Z = 0.27, p = 0.78). Publication bias was not detected. Conclusion BBR exerted anti-tumor effects in a variety of tumors in vivo, especially breast cancer and lung cancer, and the evidence was still insufficient in colorectal cancer and gastric cancer. Background Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients. Objectives Our aim was to investigate the impact of BBR on various cancers in healthy animals to promote the transformation from bench to bed. Search methods PubMed, Embase, Springer, and Cochrane databases were searched from January 2000 to October 2018 for relevant articles. Selection criteria Only published studies focusing on the relationship between BBR and various cancers in vivo were qualified. Two review authors independently assessed the risk of bias for each study, and any disagreement was resolved by discussion or by involving a third assessor. Results A total of 26 studies from 2000 to 2018, focusing on various cancer types, including breast cancer, liver cancer, colorectal cancer, nasopharyngeal carcinoma, lung cancer, gastric cancer, neuroepithelial cancer, endometrial carcinoma, esophageal cancer, tongue cancer, cholangiocarcinoma, and sarcoma were included. Overall, BBR reduced tumor volume (SMD =3.72, 95% CI: 2.89, 4.56, Z = 8.73, p < 0.00001) and tumor weight (SMD =2.35, 95% CI: 1.51, 3.19, Z = 5.50, p < 0.00001) in a linear The dose-response relationship (Pearson r = - 0.6717, p < 0.0001 in tumor volume analysis; Pearson r = - 0.7704, p < 0.0005 in tumor weight analysis). BBR inhibited angiogenesis in tumor tissues (SMD = 4.29, 95% CI: 2.14, 6.44, Z = 3.92, p < 0.00001), but it had no significant effect on the body weight of experimental animals (SMD = 0.11, 95% CI: - 0.70, 0.92, Z = 0.27, p = 0.78). Publication bias was not detected. Conclusion BBR exerted anti-tumor effects in a variety of tumors in vivo, especially breast cancer and lung cancer, and the evidence was still insufficient in colorectal cancer and gastric cancer. Keywords: Berberine, Cancer, Experimental animals, Meta-analysis Background Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients. Objectives Our aim was to investigate the impact of BBR on various cancers in healthy animals to promote the transformation from bench to bed. Search methods PubMed, Embase, Springer, and Cochrane databases were searched from January 2000 to October 2018 for relevant articles. Selection criteria Only published studies focusing on the relationship between BBR and various cancers in vivo were qualified. Two review authors independently assessed the risk of bias for each study, and any disagreement was resolved by discussion or by involving a third assessor. Results A total of 26 studies from 2000 to 2018, focusing on various cancer types, including breast cancer, liver cancer, colorectal cancer, nasopharyngeal carcinoma, lung cancer, gastric cancer, neuroepithelial cancer, endometrial carcinoma, esophageal cancer, tongue cancer, cholangiocarcinoma, and sarcoma were included. Overall, BBR reduced tumor volume (SMD =3.72, 95% CI: 2.89, 4.56, Z = 8.73, p < 0.00001) and tumor weight (SMD =2.35, 95% CI: 1.51, 3.19, Z = 5.50, p < 0.00001) in a linear The dose–response relationship (Pearson r = − 0.6717, p < 0.0001 in tumor volume analysis; Pearson r = − 0.7704, p < 0.0005 in tumor weight analysis). BBR inhibited angiogenesis in tumor tissues (SMD = 4.29, 95% CI: 2.14, 6.44, Z = 3.92, p < 0.00001), but it had no significant effect on the body weight of experimental animals (SMD = 0.11, 95% CI: − 0.70, 0.92, Z = 0.27, p = 0.78). Publication bias was not detected. Conclusion BBR exerted anti-tumor effects in a variety of tumors in vivo, especially breast cancer and lung cancer, and the evidence was still insufficient in colorectal cancer and gastric cancer. Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients. Our aim was to investigate the impact of BBR on various cancers in healthy animals to promote the transformation from bench to bed. A total of 26 studies from 2000 to 2018, focusing on various cancer types, including breast cancer, liver cancer, colorectal cancer, nasopharyngeal carcinoma, lung cancer, gastric cancer, neuroepithelial cancer, endometrial carcinoma, esophageal cancer, tongue cancer, cholangiocarcinoma, and sarcoma were included. Overall, BBR reduced tumor volume (SMD =3.72, 95% CI: 2.89, 4.56, Z = 8.73, p < 0.00001) and tumor weight (SMD =2.35, 95% CI: 1.51, 3.19, Z = 5.50, p < 0.00001) in a linear The dose-response relationship (Pearson r = - 0.6717, p < 0.0001 in tumor volume analysis; Pearson r = - 0.7704, p < 0.0005 in tumor weight analysis). BBR inhibited angiogenesis in tumor tissues (SMD = 4.29, 95% CI: 2.14, 6.44, Z = 3.92, p < 0.00001), but it had no significant effect on the body weight of experimental animals (SMD = 0.11, 95% CI: - 0.70, 0.92, Z = 0.27, p = 0.78). Publication bias was not detected. BBR exerted anti-tumor effects in a variety of tumors in vivo, especially breast cancer and lung cancer, and the evidence was still insufficient in colorectal cancer and gastric cancer. Abstract Background Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients. Objectives Our aim was to investigate the impact of BBR on various cancers in healthy animals to promote the transformation from bench to bed. Search methods PubMed, Embase, Springer, and Cochrane databases were searched from January 2000 to October 2018 for relevant articles. Selection criteria Only published studies focusing on the relationship between BBR and various cancers in vivo were qualified. Two review authors independently assessed the risk of bias for each study, and any disagreement was resolved by discussion or by involving a third assessor. Results A total of 26 studies from 2000 to 2018, focusing on various cancer types, including breast cancer, liver cancer, colorectal cancer, nasopharyngeal carcinoma, lung cancer, gastric cancer, neuroepithelial cancer, endometrial carcinoma, esophageal cancer, tongue cancer, cholangiocarcinoma, and sarcoma were included. Overall, BBR reduced tumor volume (SMD =3.72, 95% CI: 2.89, 4.56, Z = 8.73, p < 0.00001) and tumor weight (SMD =2.35, 95% CI: 1.51, 3.19, Z = 5.50, p < 0.00001) in a linear The dose–response relationship (Pearson r = − 0.6717, p < 0.0001 in tumor volume analysis; Pearson r = − 0.7704, p < 0.0005 in tumor weight analysis). BBR inhibited angiogenesis in tumor tissues (SMD = 4.29, 95% CI: 2.14, 6.44, Z = 3.92, p < 0.00001), but it had no significant effect on the body weight of experimental animals (SMD = 0.11, 95% CI: − 0.70, 0.92, Z = 0.27, p = 0.78). Publication bias was not detected. Conclusion BBR exerted anti-tumor effects in a variety of tumors in vivo, especially breast cancer and lung cancer, and the evidence was still insufficient in colorectal cancer and gastric cancer. Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients. Our aim was to investigate the impact of BBR on various cancers in healthy animals to promote the transformation from bench to bed. PubMed, Embase, Springer, and Cochrane databases were searched from January 2000 to October 2018 for relevant articles. Only published studies focusing on the relationship between BBR and various cancers in vivo were qualified. Two review authors independently assessed the risk of bias for each study, and any disagreement was resolved by discussion or by involving a third assessor. A total of 26 studies from 2000 to 2018, focusing on various cancer types, including breast cancer, liver cancer, colorectal cancer, nasopharyngeal carcinoma, lung cancer, gastric cancer, neuroepithelial cancer, endometrial carcinoma, esophageal cancer, tongue cancer, cholangiocarcinoma, and sarcoma were included. Overall, BBR reduced tumor volume (SMD =3.72, 95% CI: 2.89, 4.56, Z = 8.73, p < 0.00001) and tumor weight (SMD =2.35, 95% CI: 1.51, 3.19, Z = 5.50, p < 0.00001) in a linear The dose-response relationship (Pearson r = - 0.6717, p < 0.0001 in tumor volume analysis; Pearson r = - 0.7704, p < 0.0005 in tumor weight analysis). BBR inhibited angiogenesis in tumor tissues (SMD = 4.29, 95% CI: 2.14, 6.44, Z = 3.92, p < 0.00001), but it had no significant effect on the body weight of experimental animals (SMD = 0.11, 95% CI: - 0.70, 0.92, Z = 0.27, p = 0.78). Publication bias was not detected. BBR exerted anti-tumor effects in a variety of tumors in vivo, especially breast cancer and lung cancer, and the evidence was still insufficient in colorectal cancer and gastric cancer. |
| ArticleNumber | 589 |
| Audience | Academic |
| Author | Xu, Jianhao Yuan, Xuya Yu, Na Zhang, Yusong Long, Yuming Ni, Liwei Wu, Runhong Tao, Jialong |
| Author_xml | – sequence: 1 givenname: Jianhao surname: Xu fullname: Xu, Jianhao organization: Department of Pathology, Kunshan First People’s Hospital Affiliated to Jiangsu University – sequence: 2 givenname: Yuming surname: Long fullname: Long, Yuming organization: Department of Oncology, The Second Affiliated Hospital of Soochow University – sequence: 3 givenname: Liwei surname: Ni fullname: Ni, Liwei organization: Department of Oncology, The Second Affiliated Hospital of Soochow University – sequence: 4 givenname: Xuya surname: Yuan fullname: Yuan, Xuya organization: Department of Oncology, The Second Affiliated Hospital of Soochow University – sequence: 5 givenname: Na surname: Yu fullname: Yu, Na organization: Department of Oncology, The Second Affiliated Hospital of Soochow University – sequence: 6 givenname: Runhong surname: Wu fullname: Wu, Runhong organization: Department of Oncology, The Second Affiliated Hospital of Soochow University – sequence: 7 givenname: Jialong surname: Tao fullname: Tao, Jialong organization: Department of Oncology, The Second Affiliated Hospital of Soochow University – sequence: 8 givenname: Yusong surname: Zhang fullname: Zhang, Yusong email: zhangyusong19@163.com organization: Department of Oncology, The Second Affiliated Hospital of Soochow University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31208348$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kltr3DAQhU1JaZJtf0BfiqFQ2genkizLch4KIfQSCBR6eRaSPNposaWt5N0m0B_f2WzSZENbbBgz_s7x6HgOi70QAxTFc0qOKJXibaZMyqYitKuatqMVfVQcUN7SinHS7t173i8Oc14QQltJ5JNiv6aMyJrLg-LXSZi81cFCKsE5sFMZXWkg4e0DlEZn6MsYSrhcYmeEMOmh1MGPWMbYw5A3grVOPq5yuXXKx6Uu81WeYNToXiZYe_iJqr4cYdKVDnq4yj4_LR47PWR4dlNnxfcP77-dfqrOP388Oz05r6wQcqpETSRwY6C2WraOSiktA6Zrx00jibZN71pNW24EVhCWc2YkNaxnTDhr6llxtvXto16oJR5DpysVtVfXjZjmSiccdADVm65vm6ajlDsOVkgHrTWE8K4mVhqCXu-2XsuVGaG3GEjSw47p7pvgL9Q8rpXAUQXnaPD6xiDFHyvIkxp9tjAMOgBGqBjjTDJKuw368gG6iKuE4V1TNZO0Ec0dNdd4AB9cxO_ajak6aTrSCtHgz54VR3-h8Oph9Bb3ynns7wje7AiQmeBymutVzurs65dd9tU99gL0MF3kOKwmH0PeBV_cT-9PbLcLiUC7BWyKOSdwyvpJb3xwXD8oStRm9dV29RWuvtqsvqKopA-Ut-b_07CtJiMb5pDuAv636DeEgxSf |
| CitedBy_id | crossref_primary_10_1080_15422119_2024_2423403 crossref_primary_10_62347_KSKH3925 crossref_primary_10_3390_ijms25042100 crossref_primary_10_1111_ajco_14134 crossref_primary_10_3389_fphar_2020_01073 crossref_primary_10_1007_s12032_022_01818_5 crossref_primary_10_3390_antiox11010015 crossref_primary_10_1080_14756366_2022_2118268 crossref_primary_10_1016_j_intimp_2025_114344 crossref_primary_10_2174_0113862073297703240613073134 crossref_primary_10_3390_pharmaceutics13020143 crossref_primary_10_1002_cnr2_70012 crossref_primary_10_1016_j_ejphar_2020_173655 crossref_primary_10_1155_2019_6831520 crossref_primary_10_1016_j_bbadis_2020_165897 crossref_primary_10_1002_ptr_7032 crossref_primary_10_3390_cancers13184502 crossref_primary_10_1007_s42729_020_00260_8 crossref_primary_10_1016_j_bcab_2020_101621 crossref_primary_10_3390_biomedicines12061339 crossref_primary_10_1007_s10989_019_09914_3 crossref_primary_10_1002_ptr_7538 crossref_primary_10_1186_s12645_021_00096_6 crossref_primary_10_3390_molecules26185501 crossref_primary_10_3390_ijms222111466 crossref_primary_10_1016_j_phymed_2022_154314 crossref_primary_10_3390_ph14020157 crossref_primary_10_2174_0929867329666220224112811 crossref_primary_10_1002_cam4_3660 crossref_primary_10_3390_ma14206114 crossref_primary_10_3390_molecules25225233 crossref_primary_10_3390_molecules26020376 crossref_primary_10_3389_fphar_2022_843872 crossref_primary_10_1002_ptr_8255 crossref_primary_10_2217_bmt_2020_0007 crossref_primary_10_1016_j_clnesp_2020_04_010 crossref_primary_10_1016_j_fitote_2024_106118 crossref_primary_10_1016_j_jep_2020_113435 crossref_primary_10_3390_biomedicines11123317 crossref_primary_10_1016_j_ejmech_2019_111951 crossref_primary_10_3390_nu15194245 crossref_primary_10_1016_j_jddst_2025_106924 crossref_primary_10_1007_s12010_023_04395_z crossref_primary_10_1016_j_bmc_2023_117156 |
| Cites_doi | 10.4103/1008-682X.169997 10.1371/annotation/82b96c01-6435-4856-80a6-0176b1986e32 10.1016/j.pharep.2018.07.005 10.1016/j.biopha.2016.10.111 10.3892/ol.2013.1434 10.21873/anticanres.12741 10.1159/000487171 10.3347/kjp.2013.51.6.711 10.1111/1440-1681.12343 10.3892/mmr.2016.5361 10.1016/j.biopha.2017.08.045 10.1142/S0192415X15500846 10.1186/s12885-015-1596-z 10.1016/j.bbrc.2018.05.063 10.1007/s11626-016-0044-y 10.1016/j.phymed.2009.02.015 10.1016/j.ejca.2008.07.040 10.1002/mc.20453 10.1371/journal.pone.0093310 10.1002/mc.20690 10.18632/oncotarget.12589 10.1016/j.phymed.2012.05.009 10.1038/jcbfm.2010.220 10.1037/h0026256 10.1093/carcin/bgv103 10.3892/mmr.2015.3926 10.1186/1471-2407-13-619 10.1016/j.bbadis.2014.12.004 10.1016/j.biopha.2018.04.161 10.1016/j.fitote.2009.10.010 10.1016/j.biopha.2018.03.132 10.2147/OTT.S104729 10.1016/j.biopha.2017.05.069 10.1210/jc.2007-2404 10.3389/fphar.2018.01150 10.1080/10286020802675076 10.18632/oncotarget.9968 10.3390/molecules171011294 10.1007/s11418-013-0766-z 10.1080/01635581.2015.1085581 10.1038/onc.2017.296 10.3892/or.2017.5489 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-019-5791-1 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Proquest Health and Medical Complete ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 20 |
| ExternalDocumentID | oai_doaj_org_article_db9d7559114f4ec68fe7cb004930c8b0 PMC6580644 A590766508 31208348 10_1186_s12885_019_5791_1 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GrantInformation_xml | – fundername: the second affiliated hospital of Soochow university clinical discipline group project funding grantid: XKQ 2015008 – fundername: the second affiliated hospital of Soochow university pre-research project grantid: SDFEYGJ1609 – fundername: the project from national key laboratory of radiation medicine grantid: GZK1201820 – fundername: international team of gastrointestinal tumor project funding grantid: SZYJTD201804 – fundername: ; grantid: XKQ 2015008 – fundername: ; grantid: SDFEYGJ1609 – fundername: ; grantid: SZYJTD201804 – fundername: ; grantid: GZK1201820 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c668t-6308e4bbe3ca87f1888c2e2a3f4b580ac5df7a174b6f7ae6c442b81b2d226fcb3 |
| IEDL.DBID | PIMPY |
| ISICitedReferencesCount | 58 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000471859100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2407 |
| IngestDate | Fri Oct 03 12:44:41 EDT 2025 Tue Nov 04 01:39:04 EST 2025 Fri Sep 05 13:30:36 EDT 2025 Mon Oct 06 18:38:13 EDT 2025 Tue Nov 11 10:07:28 EST 2025 Tue Nov 04 18:02:29 EST 2025 Thu Nov 13 15:32:12 EST 2025 Thu May 22 20:58:49 EDT 2025 Thu Jan 02 22:59:30 EST 2025 Sat Nov 29 04:30:37 EST 2025 Tue Nov 18 21:26:56 EST 2025 Sat Sep 06 07:18:14 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Berberine Experimental animals Cancer Meta-analysis |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c668t-6308e4bbe3ca87f1888c2e2a3f4b580ac5df7a174b6f7ae6c442b81b2d226fcb3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.proquest.com/publiccontent/docview/2243281565?pq-origsite=%requestingapplication% |
| PMID | 31208348 |
| PQID | 2243281565 |
| PQPubID | 44074 |
| PageCount | 20 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_db9d7559114f4ec68fe7cb004930c8b0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6580644 proquest_miscellaneous_2242821194 proquest_journals_2243281565 gale_infotracmisc_A590766508 gale_infotracacademiconefile_A590766508 gale_incontextgauss_ISR_A590766508 gale_healthsolutions_A590766508 pubmed_primary_31208348 crossref_citationtrail_10_1186_s12885_019_5791_1 crossref_primary_10_1186_s12885_019_5791_1 springer_journals_10_1186_s12885_019_5791_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-06-17 |
| PublicationDateYYYYMMDD | 2019-06-17 |
| PublicationDate_xml | – month: 06 year: 2019 text: 2019-06-17 day: 17 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC cancer |
| PublicationTitleAbbrev | BMC Cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | SK Katiyar (5791_CR26) 2010; 48 A Refaat (5791_CR12) 2013; 6 K Su (5791_CR16) 2016; 7 C Chen (5791_CR1) 2014; 42 MA James (5791_CR25) 2011; 50 HL Li (5791_CR28) 2016; 14 S Kim (5791_CR13) 2018; 45 Y Hu (5791_CR47) 2014; 9 H Ruan (5791_CR21) 2017; 36 J Wang (5791_CR27) 2016; 7 T Zhu (5791_CR38) 2015; 43 Y Hu (5791_CR43) 2010; 81 5791_CR6 Z Lei (5791_CR35) 2012; 17 Y Hu (5791_CR46) 2012; 19 HY You (5791_CR42) 2016; 52 Y Zhang (5791_CR45) 2008; 93 MT Chi (5791_CR19) 2015; 1852 KC Karnam (5791_CR14) 2017; 92 D Elisa (5791_CR15) 2015; 42 L Yunfang (5791_CR39) 2008; 44 I Norio (5791_CR20) 2010; 99 Y Wang (5791_CR31) 2018; 103 Y Cai (5791_CR22) 2014; 68 YT Ho (5791_CR33) 2009; 16 T Yuantong (5791_CR4) 2016; 18 J Cohen (5791_CR8) 1968; 70 KK Hui (5791_CR7) 1989; 249 K Ren (5791_CR32) 2016; 84 Y Zhao (5791_CR11) 2017; 95 A Pandey (5791_CR41) 2015; 67 J Li (5791_CR18) 2015; 12 KP Jabbarzadeh (5791_CR36) 2018; 71 W Guan-Yu (5791_CR17) 2009; 11 MASSIMILIANO CAZZANIGA (5791_CR3) 2018; 38 E Pierpaoli (5791_CR10) 2015; 36 J Wang (5791_CR29) 2015; 15 Y Sun (5791_CR30) 2018; 102 Z Xu (5791_CR44) 2012; 7 S Kim (5791_CR2) 2018; 501 C Wang (5791_CR23) 2017; 37 H Liu (5791_CR5) 2016; 9 MT Chi (5791_CR24) 2013; 13 YH Su (5791_CR40) 2015; 1853 P Nattapong (5791_CR34) 2013; 51 M Cazzaniga (5791_CR37) 2018; 38 C Kilkenny (5791_CR9) 2011; 31 |
| References_xml | – volume: 18 start-page: 607 year: 2016 ident: 5791_CR4 publication-title: Asian J Androl doi: 10.4103/1008-682X.169997 – volume: 7 start-page: e42529 year: 2012 ident: 5791_CR44 publication-title: PLoS One doi: 10.1371/annotation/82b96c01-6435-4856-80a6-0176b1986e32 – volume: 71 start-page: 13 year: 2018 ident: 5791_CR36 publication-title: Pharmacol Rep doi: 10.1016/j.pharep.2018.07.005 – volume: 84 start-page: 1748 year: 2016 ident: 5791_CR32 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2016.10.111 – volume: 1853 start-page: 2261 year: 2015 ident: 5791_CR40 publication-title: BBA - Molecular Cell Research – volume: 249 start-page: 492 year: 1989 ident: 5791_CR7 publication-title: Journal of Pharmacology & Experimental Therapeutics – volume: 6 start-page: 840 year: 2013 ident: 5791_CR12 publication-title: Oncol Lett doi: 10.3892/ol.2013.1434 – volume: 38 start-page: 4393 year: 2018 ident: 5791_CR37 publication-title: Anticancer Res doi: 10.21873/anticanres.12741 – volume: 45 start-page: 795 year: 2018 ident: 5791_CR13 publication-title: Cell Physiol Biochem doi: 10.1159/000487171 – volume: 51 start-page: 711 year: 2013 ident: 5791_CR34 publication-title: Korean J Parasitol doi: 10.3347/kjp.2013.51.6.711 – volume: 42 start-page: 225 year: 2015 ident: 5791_CR15 publication-title: Clinical & Experimental Pharmacology & Physiology doi: 10.1111/1440-1681.12343 – volume: 99 start-page: 286 year: 2010 ident: 5791_CR20 publication-title: Int J Cancer – volume: 14 start-page: 1430 year: 2016 ident: 5791_CR28 publication-title: Mol Med Rep doi: 10.3892/mmr.2016.5361 – volume: 95 start-page: 18 year: 2017 ident: 5791_CR11 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2017.08.045 – volume: 43 start-page: 1550084 year: 2015 ident: 5791_CR38 publication-title: Am J Chinese Med. doi: 10.1142/S0192415X15500846 – volume: 15 start-page: 595 year: 2015 ident: 5791_CR29 publication-title: BMC Cancer doi: 10.1186/s12885-015-1596-z – volume: 501 start-page: 765 year: 2018 ident: 5791_CR2 publication-title: Biochemical & Biophysical Research Communications doi: 10.1016/j.bbrc.2018.05.063 – volume: 52 start-page: 1 year: 2016 ident: 5791_CR42 publication-title: In Vitro Cellular & Developmental Biology - Animal doi: 10.1007/s11626-016-0044-y – volume: 16 start-page: 887 year: 2009 ident: 5791_CR33 publication-title: Phytomedicine. doi: 10.1016/j.phymed.2009.02.015 – volume: 44 start-page: 2425 year: 2008 ident: 5791_CR39 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.07.040 – volume: 48 start-page: 24 year: 2010 ident: 5791_CR26 publication-title: Mol Carcinogen doi: 10.1002/mc.20453 – volume: 9 start-page: e93310 year: 2014 ident: 5791_CR47 publication-title: PLoS One doi: 10.1371/journal.pone.0093310 – volume: 50 start-page: 1 year: 2011 ident: 5791_CR25 publication-title: Mol Carcinog doi: 10.1002/mc.20690 – volume: 7 start-page: 76076 year: 2016 ident: 5791_CR27 publication-title: Oncotarget. doi: 10.18632/oncotarget.12589 – volume: 42 start-page: 1450066 year: 2014 ident: 5791_CR1 publication-title: Am J Chinese Med – volume: 19 start-page: 861 year: 2012 ident: 5791_CR46 publication-title: Phytomedicine doi: 10.1016/j.phymed.2012.05.009 – volume: 31 start-page: 991 year: 2011 ident: 5791_CR9 publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2010.220 – volume: 70 start-page: 213 year: 1968 ident: 5791_CR8 publication-title: Psychol Bull doi: 10.1037/h0026256 – volume: 36 start-page: 1169 year: 2015 ident: 5791_CR10 publication-title: Carcinogenesis. doi: 10.1093/carcin/bgv103 – volume: 12 start-page: 4572 year: 2015 ident: 5791_CR18 publication-title: Mol Med Rep doi: 10.3892/mmr.2015.3926 – volume: 13 start-page: 619 year: 2013 ident: 5791_CR24 publication-title: BMC Cancer doi: 10.1186/1471-2407-13-619 – volume: 1852 start-page: 541 year: 2015 ident: 5791_CR19 publication-title: BBA - Molecular Basis of Disease doi: 10.1016/j.bbadis.2014.12.004 – volume: 103 start-page: 1287 year: 2018 ident: 5791_CR31 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2018.04.161 – volume: 81 start-page: 358 year: 2010 ident: 5791_CR43 publication-title: Fitoterapia doi: 10.1016/j.fitote.2009.10.010 – volume: 102 start-page: 699 year: 2018 ident: 5791_CR30 publication-title: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie doi: 10.1016/j.biopha.2018.03.132 – volume: 38 start-page: 4393 issue: 8 year: 2018 ident: 5791_CR3 publication-title: Anticancer Research doi: 10.21873/anticanres.12741 – volume: 9 start-page: 4121 year: 2016 ident: 5791_CR5 publication-title: Oncotargets & Therapy doi: 10.2147/OTT.S104729 – volume: 92 start-page: 207 year: 2017 ident: 5791_CR14 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2017.05.069 – volume: 93 start-page: 2559 year: 2008 ident: 5791_CR45 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2007-2404 – ident: 5791_CR6 doi: 10.3389/fphar.2018.01150 – volume: 11 start-page: 219 year: 2009 ident: 5791_CR17 publication-title: J Asian Nat Prod Res doi: 10.1080/10286020802675076 – volume: 7 start-page: 45849 year: 2016 ident: 5791_CR16 publication-title: Oncotarget. doi: 10.18632/oncotarget.9968 – volume: 17 start-page: 11294 year: 2012 ident: 5791_CR35 publication-title: Molecules. doi: 10.3390/molecules171011294 – volume: 68 start-page: 53 year: 2014 ident: 5791_CR22 publication-title: J Nat Med-Tokyo doi: 10.1007/s11418-013-0766-z – volume: 67 start-page: 1293 year: 2015 ident: 5791_CR41 publication-title: Nutrition & Cancer-an International Journal doi: 10.1080/01635581.2015.1085581 – volume: 36 start-page: 6906 year: 2017 ident: 5791_CR21 publication-title: Oncogene. doi: 10.1038/onc.2017.296 – volume: 37 start-page: 2109 issue: 4 year: 2017 ident: 5791_CR23 publication-title: Oncol Rep doi: 10.3892/or.2017.5489 |
| SSID | ssj0017808 |
| Score | 2.4976494 |
| SecondaryResourceType | review_article |
| Snippet | Background
Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients.... Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients. Our aim was to... Background Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients.... Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer patients. Our aim was to... Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer... Abstract Background Numerous studies have explored the anti-tumor effect of berberine (BBR), but little clinical evidence guides the use of BBR in cancer... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 589 |
| SubjectTerms | Analysis Angiogenesis Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Animal models Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Berberine Berberine - administration & dosage Berberine - adverse effects Berberine - therapeutic use Berberis - chemistry Bias Biliary tract cancer Biomedical and Life Sciences Biomedicine Body Weight Breast cancer Cancer Cancer patients Cancer Research Cancer treatment Carcinoma Care and treatment Cholangiocarcinoma Colorectal cancer Colorectal carcinoma Cricetinae Disease Models, Animal Dogs Dose-Response Relationship, Drug Endometrial cancer Endometrium Esophageal cancer Esophagus Experimental animals Gastric cancer Gastrointestinal diseases Guinea Pigs Haplorhini Health aspects Health Promotion and Disease Prevention Horses Humans Liver Liver cancer Lung cancer Lung carcinoma Medical and radiation oncology Medical research Medicine/Public Health Meta-analysis Mice Nasopharyngeal carcinoma Neoplasms - drug therapy Neoplasms - metabolism Nutrition research Oncology Oral cancer Phytotherapy Plant Extracts - therapeutic use Practice guidelines (Medicine) Rabbits Rats Research Article Sarcoma Sheep Software Statistical analysis Studies Surgical Oncology Systematic review Throat cancer Tongue cancer Traditional Chinese medicine Tumor Burden Tumors Uterine cancer |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yiPgiflvv1CiCoJRrmjQfvq3ioaCH-MW9hTRNzwWvPba79-Qf70ya3dueqC8-FZpJSGcmyUwz8xtCnvLaaS4rnxeNrnLBnMhNa1jOPPfGmVKziKX37b06PNRHR-bjVqkvjAkb4YFHxu03tWkUmL1gt7cieKnboHwM0OGF13X01sHqWTtT6f5A6UKnO0ym5f4Au7DGIDWTVwpnMjmFIlj_71vy1pl0MV7ywqVpPIsOrpNryYiks3HyN8il0N0kVz6ka_Jb5Oesw1_UIM8FHQM2aN_SGjgYk_0oHl0N7Tu6je9PXTc_gUesjTNghzPwo_vVQMeRhpfU0XPgZzomvUCvhp6Epctdgje5Tb4evPny-m2eyizkXkq9zCUvdBB1Hbh3WrUMfGJfhtLxVtSVLpyvmlY58FxqCc8gvRBlDdZu2YDp1vqa3yE7Xd-Fe4QG5hiSFb7hmEHnVMWU484HI5wr2owUa7ZbnzDIsRTGDxt9ES3tKCkLkrIoKcsy8nzT5XQE4Pgb8SuU5YYQsbPjC9AomzTK_kujMvIINcGOiaibHcDOKlMoiRZtRp5ECsTP6DBA59ithsG--_xpQvQsEbU9fKN3Kd8BOIWQWxPKvQklLHA_bV6rpE0bzGDB8uIlIv1UGXm8acaeGDTXBdAOpAGHmjEjMnJ31OANZziDVcMFDK4muj1h3bSlm3-P8ONgs4IdC2O-WK-C82n9UTL3_4dkdsnVEtcwlo5Se2RnuViFB-SyP1vOh8XDuAP8ApAhXpU priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9QwDI9gILQXvhmFAQEhIYEqmiZtEt4OxAQSTGiDaW9RmqbjJNai692e-OOx01y3jg8Jnio1TtS6tmPX9i-EPOWVVbwsXJrVqkgFsyLVjWYpc9xpq3PFApbewQe5u6sOD_Wn2Mfdr6vd1ynJYKmDWqvyZQ-WVGGhmU4LiatdJJdgt1OojXv7B2PqQKpMxfTlb6dNNqCA0_-rNT6zHZ0vlTyXLw3b0M61_3qB6-Rq9DrpbBCTG-SCb2-SKx9jXv0W-TFr8Z82CMCCDhUetGtoBSwP3YEU97qadi09eyAAte38GC7hMJ0eJ5xA4N2tejqs1L-ilp4iRdOhSwZm1fTYL21qIx7KbfJl5-3nN-_SeC5D6spSLdOSZ8qLqvLcWSUbBkG0y31ueSOqQmXWFXUjLYQ6VQlXXzoh8grc47wGX69xFb9DNtqu9XcJ9cwyJMtczbHlzsqCScut81pYmzUJydYfy7gIWo5nZ3wzIXhRpRm4aoCrBrlqWEKej1O-D4gdfyN-jRIwEiLYdrjRLY5M1F1TV7qWEHlB6NgI70rVeOlCjRjPnKqyhDxC-TFD5-poMsys0Jks0QVOyJNAgYAbLVb0HNlV35v3-3sTomeRqOngHZ2NDRLAKcTomlBuTyjBIrjp8FqQTbRIvQFXjecIDVQk5PE4jDOxyq71IB1IAxE4Y1okZGuQ-5EznOXgrQtYXE40YsK66Ug7_xrwysHJBccX1nyx1ovTx_rjl7n3T9T3yWaOioWHSsltsrFcrPwDctmdLOf94mEwED8Bt0hiMw priority: 102 providerName: Springer Nature |
| Title | Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis |
| URI | https://link.springer.com/article/10.1186/s12885-019-5791-1 https://www.ncbi.nlm.nih.gov/pubmed/31208348 https://www.proquest.com/docview/2243281565 https://www.proquest.com/docview/2242821194 https://pubmed.ncbi.nlm.nih.gov/PMC6580644 https://doaj.org/article/db9d7559114f4ec68fe7cb004930c8b0 |
| Volume | 19 |
| WOSCitedRecordID | wos000471859100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdYixAvfH8ERjEICQkUNc6XHV5QhzYxiVVVB1N5shzHGZVYMpp2T_zx3DluuwyxJ14aNT5bsX0-39l3vyPkTZQrEaWJ9oNCJH7MVOxnZcZ8piOdqSwUzGLpnXzh47GYzbKJC49unFvlWiZaQd2iPaPfNgjhYVFrPDEfwsYThQh0knw8_-VjDim8a3UJNXZIH4G3RI_0J4dHk--bWwUuAuFuNplIhw3IZoGua5mfcPy-zt5kIfz_FtSXdqqrXpRXrlLtDnVw9__27R654zRVOmpZ6z65YaoH5NaRu4t_SH6PKjwHB6ZZ0NYrhNYlzWGabEQhxf2xoHVFLycRoKqan8HDJuBpsMIFGOv1qqFtS80HqugWXZq2kTVQq6BnZql85TBUHpFvB_tfP332XS4HX6epWPppFAgT57mJtBK8ZGB469CEKirjPBGB0klRcgXmUZ7C06Q6jsMcVOqwAP2w1Hn0mPSqujJPCTVMMSQLdBFhmJ7iCeMqUtpksVJB6ZFgPYtSO6BzzLfxU1qDR6SynXgJEy9x4iXzyLtNlfMW5eM64j1kjQ0hAnTbF_XiVLr1Los8KzhYa2BulrHRqSgN19avLAq0yAOPvETGkm2060bMyFGSBTxFtdkjry0FgnRU6AV0qlZNIw-Ppx2it46orKGPWrmgChgpxPXqUO52KEGK6G7xmjWlk2KN3HKiR15tirEmeuZVBrgDacBqZyyLPfKkXRCbkYlYCBp-DI3zzlLpDF23pJr_sBjnoBiDsgxtvl8vqu1n_XNmnl3fiefkdoiLHTNP8V3SWy5W5gW5qS-W82YxIDt8xu2vGJD-3v54Mh3YE5qBEyPwb3p88ge76n7t |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQMAL90tgMINASKBocZzEDhJC5TKtWjchNlDfjOM4oxJLRtMNIfGb-I2c46TpMsTe9sBTpPrYqp3v3OJzIeQJz7TkSWz8IJexHzEd-WmRMp8ZblKdhpK5WnqfR2J7W47H6Ycl8nueC4NhlXOZ6AR1Xhn8Rr4GqoaHWNokfn3w3ceuUXi7Om-h0cBi0_78AS5b_Wr4Dt7v0zBcf7_7dsNvuwr4JknkzE94IG2UZZYbLUXBwAU0oQ01L6IsloE2cV4IDYZ6lsDTJiaKwgyMuzAHS6UwGYd1z5HzIMcFhpCJcefgMSED2d6cMpms1SD7JYbGpX4scP893edaBPytCI5pwpNRmieuap0GXL_6v53dNXKltbXpoGGO62TJljfIxa02muAm-TUo8Us-wH5Km7gWWhU0A6C5nEiKGj6nVUmPt0Ggupzsw8O1EKpxwpGeYiAxbVaqX1JNF_WxaZMbBLNyum9n2tdtFZhb5NOZ7P02WS6r0t4l1DLNkCwwOcdEQy1iJjTXxqaR1kHhkWCOE2XaUu3YMeSbci6bTFQDLQXQUggtxTzyvJty0NQpOY34DYKvI8QS4-6HarqnWoml8izNBfib4DAXkTWJLKwwLjKOB0ZmgUdWEbqqydftBKUaxGkgEjT8PfLYUWCZkRLjmPb0YV2r4c7HHtGzlqioYI9Gt2khcFJYmaxHudKjBDlo-sNz8KtWDtdqgXyPPOqGcSbGFpYW0IE0ocRCh5FH7jQs150MZyH4KBEsLnrM2Du6_kg5-eqqtINpD-Y-rPlizraLv_XPN3Pv9E2skksbu1sjNRpub94nl0MULdhHS6yQ5dn00D4gF8zRbFJPHzrBRMmXs-bmPybjy1I |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9QwDI9goIkXvj8KgwWEhASq1jRpk_J2fExMjNPEYNpblKbJOIm10_VuT_zx2G2uW8eHhHiqdHGiq2M7dmP_TMhzXhrF88zGSaWyWDAj4sIXLGaW28IUqWIdlt7BrpxO1eFhsRf6nLarbPfVlWRf04AoTfVi66TyvYqrfKsFq6ow6ayIM4krXyZXBPYMwnB9_2C4RpAqUeEq87fTRodRh9n_q2U-dzRdTJu8cHfaHUnbN_77ZW6S68EbpZNefG6RS66-TdY_hfv2O-THpMZv3SAYc9pnftDG0xK2oqsapHgGVrSp6flGAdTUs2N4dE12WpxwCgF5s2xpv1L7mhp6hiBN--oZmFXRY7cwsQk4KXfJ1-33X95-iEO_htjmuVrEOU-UE2XpuDVKegbBtU1dargXZaYSY7PKSwMhUJnD0-VWiLQEtzmtwAf0tuT3yFrd1O4BoY4ZhmSJrTiW4hmZMWm4sa4QxiQ-Islq47QNYObYU-O77oIaleueqxq4qpGrmkXk5TDlpEfy-BvxG5SGgRBBuLsfmvmRDjqtq7KoJERkEFJ64WyuvJO2yx3jiVVlEpFNlCXdV7QOpkRPsiKRObrGEXnWUSAQR42ZPkdm2bZ6Z__ziOhFIPINvKM1oXACOIXYXSPKjRElWAo7Hl4JtQ6WqtXgwvEUIYOyiDwdhnEmZt_VDqQDaSAyZ6wQEbnf68DAGc5S8OIFLC5H2jFi3Xiknn3rcMzB-QWHGNZ8tdKRs7_1x515-E_Um2R979223t2ZfnxErqWoY9h3Sm6QtcV86R6Tq_Z0MWvnTzq78RM0IG37 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anticancer+effect+of+berberine+based+on+experimental+animal+models+of+various+cancers%3A+a+systematic+review+and+meta-analysis&rft.jtitle=BMC+cancer&rft.au=Xu%2C+Jianhao&rft.au=Long%2C+Yuming&rft.au=Ni%2C+Liwei&rft.au=Yuan%2C+Xuya&rft.date=2019-06-17&rft.pub=Springer+Nature+B.V&rft.eissn=1471-2407&rft.volume=19&rft_id=info:doi/10.1186%2Fs12885-019-5791-1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |